BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 222.8 USD | +1.38% |
|
+4.33% | -13.92% |
| May. 09 | MOVES -Lazard hires veteran healthcare dealmaker Colocci as vice chairman | RE |
| May. 08 | Redburn Atlantic Adjusts Price Target on Biogen to $235 From $275, Keeps Neutral Rating | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 9.52B | Sales 2025 * | 9.55B | Capitalization | 32.43B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.9B | Net income 2025 * | 2.21B | EV / Sales 2024 * | 3.72 x |
| Net Debt 2024 * | 3.01B | Net Debt 2025 * | 536M | EV / Sales 2025 * | 3.45 x |
| P/E ratio 2024 * |
17.2
x | P/E ratio 2025 * |
14.9
x | Employees | 7,570 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.81% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biogen Inc.
More recommendations
More press releases
More news
| 1 day | +1.38% | ||
| 1 week | +4.33% | ||
| Current month | +3.69% | ||
| 1 month | +7.86% | ||
| 3 months | -7.56% | ||
| 6 months | -0.85% | ||
| Current year | -13.92% |
1 week
216.08
222.91
1 month
189.44222.91
Current year
189.44268.30
1 year
189.44319.76
3 years
187.16468.55
5 years
187.16468.55
10 years
187.16480.18
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 22-11-13 | |
| Director of Finance/CFO | 60 | 20-08-14 | |
Nicole Murphy
COO | Chief Operating Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 09-12-31 |
William Hawkins
BRD | Director/Board Member | 70 | 19-06-18 |
Caroline Dorsa
CHM | Chairman | 64 | 10-01-02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.30% | 0 M€ | -2.17% | - | |
| 3.92% | 0 M€ | 0.00% | - | |
| 3.75% | 0 M€ | 0.00% | - | |
| 2.39% | 0 M€ | +5.71% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 222.8 | +1.38% | 754,595 |
| 24-05-08 | 219.7 | +0.37% | 758,528 |
| 24-05-07 | 218.9 | -1.13% | 1,156,500 |
| 24-05-06 | 221.4 | +1.80% | 1,199,848 |
| 24-05-03 | 217.5 | +1.87% | 1,144,154 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
222.8
USD
Average target price
285.9
USD
Spread / Average Target
+28.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.92% | 32.43B | |
| -2.61% | 88.47B | |
| +2.76% | 40.71B | |
| +50.51% | 24.28B | |
| -15.25% | 15.52B | |
| -39.93% | 12.17B | |
| -9.08% | 12B | |
| -14.80% | 12.01B | |
| +6.22% | 8.87B | |
| -2.69% | 8.44B |
- Stock Market
- Equities
- BIIB Stock